乌鸦传媒

Continued OAC failed to meet noninferiority in POPular PAUSE TAVI

Randomized trial shows benefits beyond heart failure with low ejection fraction, but not survival

RESHAPE-HF2 has provocative implications for a wider pool of TEER candidates

Randomized trial "highly encouraging" for making patients feel and function better

Either choice is "acceptable" based on randomized study

Fewer people using primary prevention medications expected to result in more CVD

Eight decades after FDR's decline and death, do White House physicians owe truth to the public?

Three regimens compared head-to-head among abundant choices

Most cases were mild, and age was a predictor of disease

All-cause mortality also lower compared with nonsurgical controls

Question of clinical benefit beyond LVEF improvement will require larger trials

The amino acid mixture reduced stage 3 AKI by 44% compared with placebo

New additions to Sapien, Evolut, Navitor lines aim to ensure coronary access

Arexvy now approved for people 50 years and older at increased risk of serious outcomes